Abstract
Hereditary factor V (FV) deficiency is a rare autosomal recessive bleeding disorder caused by F5 gene mutations. The objective of this study was to investigate the p.Phe218Ser and p.Gly304Glu variants found in 2 families with hereditary FV deficiency. The FV activity (FV:C) and FV antigen (FV:Ag) were measured by clotting and ELISA, respectively. The F5 gene and sequence conservation were analyzed by direct sequencing and ClustalX-2.1-win, respectively. One proband carried a homozygous p.Phe218Ser (c.653T>C) mutation, with FV:C and FV:Ag decreased to 11 and 14%, respectively. The other proband carried a heterozygous p.Gly304Glu (c.911G>A) mutation, with FV:C and FV:Ag reduced to 55 and 62%, respectively. Phe218 and Gly304 were highly conserved in the homologous gene in 9 other species. We hypothesized that the p.Phe218Ser and p.Gly304Glu variants are deleterious and responsible for the reduction in FV:C and FV:Ag.
References
1.
Rosing
J
, Tans
G
, Govers-Riemslag
JW
, Zwaal
RF
, Hemker
HC
. The role of phospholipids and factor Va in the prothrombinase complex
. J Biol Chem
. 1980 Jan 10
;255
(1
):274
–83
.2.
Cripe
LD
, Moore
KD
, Kane
WH
. Structure of the gene for human coagulation factor V
. Biochemistry
. 1992 Apr 21
;31
(15
):3777
–85
. .3.
Song
J
, Guella
I
, Kwon
KY
, Cho
H
, Park
R
, Asselta
R
, A novel in-frame deletion in the factor V C1 domain associated with severe coagulation factor V deficiency in a Korean family
. Blood Coagul Fibrinolysis
. 2009 Mar
;20
(2
):150
–6
.4.
Lippi
G
, Favaloro
EJ
, Montagnana
M
, Manzato
F
, Guidi
GC
, Franchini
M
. Inherited and acquired factor V deficiency
. Blood Coagul Fibrinolysis
. 2011 Apr
;22
(3
):160
–6
. .5.
Kalafatis
M
, Rand
MD
, Mann
KG
. The mechanism of inactivation of human factor V and human factor Va by activated protein C
. J Biol Chem
. 1994 Dec 16
;269
(50
):31869
–80
.6.
Nicolaes
GA
, Tans
G
, Thomassen
MC
, Hemker
HC
, Pabinger
I
, Varadi
K
, Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C
. J Biol Chem
. 1995 Sep 8
;270
(36
):21158
–66
. .7.
Naderi
M
, Tabibian
S
, Alizadeh
S
, Hosseini
S
, Zaker
F
, Bamedi
T
, Congenital factor V deficiency: comparison of the severity of clinical presentations among patients with rare bleeding disorders
. Acta Haematol
. 2015
;133
(2
):148
–54
. .8.
Lak
M
, Sharifian
R
, Peyvandi
F
, Mannucci
PM
. Symptoms of inherited factor V deficiency in 35 Iranian patients
. Br J Haematol
. 1998 Dec
;103
(4
):1067
–9
. .9.
Acharya
SS
, Coughlin
A
, Dimichele
DM
. North American rare bleeding disorder study G. Rare bleeding disorder registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias
. J Thromb Haemost
. 2004 Feb
;2
(2
):248
–56
.10.
Wang
Y
, Zhu
L
, Ye
L
, Xie
Y
, Pan
J
, Wang
M
. Factor V deficiency caused by a novel nonsense mutation (Gln2031stop) in a Chinese patient
. Blood Coagul Fibrinolysis
. 2014 Apr
;25
(3
):283
–5
. .11.
Adams
TE
, Hockin
MF
, Mann
KG
, Everse
SJ
. The crystal structure of activated protein C-inactivated bovine factor Va: implications for cofactor function
. Proc Natl Acad Sci U S A
. 2004 Jun 15
;101
(24
):8918
–23
. .12.
Kalafatis
M
, Xue
J
, Lawler
CM
, Mann
KG
. Contribution of the heavy and light chains of factor Va to the interaction with factor Xa
. Biochemistry
. 1994 May 31
;33
(21
):6538
–45
. .13.
Kane
WH
, Davie
EW
. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders
. Blood
. 1988 Mar
;71
(3
):539
–55
. .14.
Ivaskevicius
V
, Jurgutis
R
, Rost
S
, Müller
A
, Schmitt
C
, Wulff
K
, Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data
. Br J Haematol
. 2001 Mar
;112
(4
):1062
–70
. .15.
Kanaji
S
, Kanaji
T
, Honda
M
, Nakazato
S
, Wakayama
K
, Tabata
Y
, Identification of four novel mutations in F5 associated with congenital factor V deficiency
. Int J Hematol
. 2009 Jan
;89
(1
):71
–5
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
